KDM3B and cancer: Given that JMJD1B deficiency increases sensitivity to PARP1 inhibition, our results suggest a potential new mechanism by which synthetic lethality is induced for cancer treatment by coupling JMJD1B gene deficiency (e.g., 5q syndrome) or LIG1 deficiency with PARP inhibitors.